Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone adjunctive therapy for mania and cognitive symptoms in bipolar I disorder
IRCT20190316043072N2Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Spironolactone + sodium valproate with Placebo + sodium valproate (2 arms). Primary endpoints: Mood symptoms improvement, Sleep quality improvement and 2 more. Started Apr 2021; status: completed.
02
Drugs
spironolactone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on IRCT20190316043072N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190316043072N2.